BioMarin Pharmaceuticals BMRN VOXZOGO — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's voxzogo — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's VOXZOGO — total revenues?
- BioMarin Pharmaceuticals (BMRN) reported VOXZOGO — total revenues of $219.88M in Q1 2026.
- How has BioMarin Pharmaceuticals's VOXZOGO — total revenues changed year-over-year?
- BioMarin Pharmaceuticals's VOXZOGO — total revenues increased by 2.9% year-over-year, from $213.75M to $219.88M.
- What is the long-term trend for BioMarin Pharmaceuticals's VOXZOGO — total revenues?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's VOXZOGO — total revenues has grown at a 254.7% compound annual growth rate (CAGR), from $5.86M to $926.92M.
- What does VOXZOGO — total revenues mean?
- The total amount of money earned from sales of a specific drug product.
- How do you interpret VOXZOGO — total revenues?
- An increase indicates growing market adoption, successful patient uptake, or expanded geographic availability, while a decrease may signal increased competition, patent expiration, or market saturation.
- How does VOXZOGO — total revenues compare across companies?
- Comparable to product-specific net sales reported by other biopharmaceutical companies for key growth assets.